Sarepta Therapeutics Inc (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, announced Henri Termeer, industry leader and former CEO of Genzyme, will be a key advisor to the Company.

“I am honored to have Henri Termeer, a pioneer of rare disease companies, serve as an advisor as we seek FDA approval for our lead product candidate and build a rare disease organization,” said Edward Kaye, M.D., Sarepta’s interim chief executive officer and chief medical officer. “Henri not only built the first world-leading biotech focused on rare disease, but more importantly created a patient-centric organization, a core value which we will remain deeply committed to at Sarepta.”

“I look forward to working closely with Edward Kaye and the entire Sarepta team during this important time in the Company’s development,” said Henri Termeer. “This is an opportunity for me to continue the work of advancing promising treatments to patients who suffer from rare and life threatening diseases, with eteplirsen, as well as with Sarepta’s pipeline of follow on exons to treat patients with DMD and other rare neuromuscular diseases.”

Henri Termeer is the former chairman, president and chief executive officer of Genzyme Corporation, where he served for nearly three decades until retiring in 2011 following the acquisition of Genzyme by Sanofi in a transaction valued at more than $20 billion. Mr. Termeer continues to be very active in the areas of humanitarian assistance, policy issues, and innovation in providing access to healthcare. Henri and his wife, Belinda, founded the Termeer Center for Targeted Therapies at Massachusetts General Hospital in 2012. He serves on the boards of numerous scientific and healthcare institutions. He is a Fellow of the American Academy of Arts and Sciences. (Original Source)

Shares of Sarepta Therapeutics Inc. closed yesterday at $30.43 . SRPT has a 1-year high of $33.16 and a 1-year low of $11.33. The stock’s 50-day moving average is $25.79 and its 200-day moving average is $16.66.

On the ratings front, Sarepta Therapeutics Inc. has been the subject of a number of recent research reports. In a report issued on June 29, Robert W. Baird analyst Brian Skorney reiterated a Buy rating on SRPT, with a price target of $34, which implies an upside of 11.7% from current levels. Separately, on the same day, Roth Capital’s Debjit Chattopadhyay maintained a Buy rating on the stock and has a price target of $45.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Brian Skorney and Debjit Chattopadhyay have a total average return of 18.5% and 30.6% respectively. Skorney has a success rate of 66.2% and is ranked #176 out of 3683 analysts, while Chattopadhyay has a success rate of 64.0% and is ranked #21.

The street is mostly Bullish on SRPT stock. Out of 11 analysts who cover the stock, 7 suggest a Buy rating and 4 recommend to Hold the stock. The 12-month average price target assigned to the stock is $35.00, which represents a potential upside of 15.0% from where the stock is currently trading.

Sarepta Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious and other diseases.